A Phase 2 interventional study of GSK1070806 and Placebo in Dermatitis, Atopic, sponsored by GlaxoSmithKline. Terminated at 89 sites in 17 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-03.
Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Dermatitis, Atopic by GlaxoSmithKline — none open to participants now, none under way, none of them phase 3. Dermatitis, Atopic · GlaxoSmithKline.
Among the 19 studies in Dermatitis, Atopic by GlaxoSmithKline, this one is the 5th largest by enrollment of the 18 interventional ones that give a count, is the only one that started in 2023, is one of 8 in phase 2, and was the 18th registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →None of the 19 studies in Dermatitis, Atopic by GlaxoSmithKline is open now. The open studies under Dermatitis, Atopic, anywhere →
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2023.
This study's enrollment of 161 is above the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 42 across the 18 interventional studies, 160 across the 1 observational. Of the 19 that completed or were terminated, 7 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 19 studies in Dermatitis, Atopic by GlaxoSmithKline, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is parallel group, placebo-controlled dose-ranging study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of GSK1070806 in adult participants with moderate to severe Atopic Dermatitis (AtD), who have previously been treated with medicated topical treatments or a biologic therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants with:
Participants may have had exposure to 1 biologic therapy meeting at least 1 of the following conditions:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received placebo subcutaneous (SC) injections for 16 weeks.
Drug: Placebo
Participants received GSK1070806 dose level 1 SC injection for 16 weeks. Dose level 1 is the lowest dose level.
Drug: GSK1070806
Participants received GSK1070806 dose level 2 SC injection for 16 weeks. Dose level 2 is greater than dose level 1.
Drug: GSK1070806
Participants received GSK1070806 dose level 3 SC injection for 16 weeks. Dose level 3 is greater than dose level 2.
Drug: GSK1070806
Participants received GSK1070806 dose level 4 SC injection for 16 weeks. Dose level 4 is greater than dose level 3.
Drug: GSK1070806
GSK1070806 will be administered.
Placebo will be administered.
Percent Change From Baseline (CFB) in Eczema Area and Severity Index (EASI) Score at Week 16
EASI scoring system is standardized clinical tool for assessment of extent (area) \& severity of atopic dermatitis(AtD). Severity of clinical signs of AtD (erythema, induration/papulation, excoriation \& lichenification) scored separately for each of 4 body regions (head \& neck, upper limbs, trunk \& lower limbs) on 4-point scale: 0=absent;1=mild;2=moderate;3=severe. EASI area score was based upon % body surface area with AtD in body region:0=0%, 1=1-9%;2=10-29%;3=30-49%;4=50-69%;5=70-89%;6=90-100%. Final EASI score was obtained by multiplying EASI area scores (0-6) with severity scores (0-3) of all 4 body regions; it ranges from 0 to 72, with higher scores= more severe or extensive condition. Baseline=last value/assessment before first dose of study treatment (ST) (Day1) based on date \& time of assessment (ToA) \& treatment. CFB =post-dose visit (Week 16) value minus Baseline value. Percent CFB was calculated by dividing CFB value by Baseline value and multiplying it by 100.
Time frame: Baseline (Day 1) and Week 16
Percent Change From Baseline (CFB) in EASI Score at Each Time Point
EASI scoring system is standardized clinical tool for assessment of extent (area) \& severity of atopic dermatitis(AtD). Severity of clinical signs of AtD (erythema, induration/papulation, excoriation \& lichenification) scored separately for each of 4 body regions (head \& neck, upper limbs, trunk \& lower limbs) on 4-point scale: 0=absent;1=mild;2=moderate;3=severe. EASI area score was based upon % body surface area with AtD in body region:0=0%, 1=1-9%;2=10-29%;3=30-49%;4=50-69%;5=70-89%;6=90-100%. Final EASI score was obtained by multiplying EASI area scores (0-6) with severity scores (0-3) of all 4 body regions; it ranges from 0 to 72, with higher scores= more severe or extensive condition. Baseline=last value/assessment before first dose of ST (Day1) based on date \& ToA \& treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Percent CFB was calculated by dividing CFB value by Baseline value and multiplying it by 100.
Time frame: Baseline (Day 1), Weeks 1, 2, 4, 6, 8, 10, 12, 14, and 16
Number of Participants Who Achieved Reduction of Greater Than or Equal to (>=) 75 Percent (%) in EASI Score From Baseline at Week 16
EASI scoring system is standardized clinical tool for assessment of extent (area) \& severity of atopic dermatitis(AtD). Severity of clinical signs of AtD (erythema, induration/papulation, excoriation \& lichenification) scored separately for each of 4 body regions (head \& neck, upper limbs, trunk \& lower limbs) on 4-point scale: 0=absent;1=mild;2=moderate;3=severe. EASI area score was based upon % body surface area with AtD in body region:0=0%, 1=1-9%;2=10-29%;3=30-49%;4=50-69%;5=70-89%;6=90-100%. Final EASI score was obtained by multiplying EASI area scores (0-6) with severity scores (0-3) of all 4 body regions; it ranges from 0 to 72, with higher scores= more severe or extensive condition. Baseline was the last value/assessment before first dose of study treatment (Day1) based on date \& time of assessment \& treatment.
Time frame: Baseline (Day 1) and Week 16
Number of Participants Who Achieved Investigator's Global Assessment (IGA) Score of 0 or 1 and Had a Reduction of >=2 Points From Baseline at Week 16
The Investigator Global Assessment (IGA) is a clinical tool for assessing the current state/severity of a participant's atopic dermatitis. It is a static 5-point morphological assessment of overall disease severity determined by the investigator, sub-investigator, or trained healthcare professional with required qualifications on a scale of 0 to 4 where, 0=clear, 1=almost clear, 2=mild, 3=moderate, and 4=severe. Higher score indicates high severity of disease. IGA 0/1 responders are participants whose IGA score is 'Clear' (0) or 'Almost Clear' (1) and had a reduction of \>=2 points from Baseline at Week 16. Baseline was the last value/assessment before the first dose of study treatment (Day 1) based on date and time of the assessment and treatment.
Time frame: Baseline (Day 1) and Week 16
Change From Baseline in Peak Pruritus Numerical Rating Scale (PP-NRS) Score at Week 16
PP-NRS is a patient reported measure of pruritus (itch) intensity assessing worst itch (in the past 24 hours). The values were evaluated using an 11-point scale (from 0 to 10), with 0 being no itch and 10 being the worst imaginable itch. Baseline was averaged from daily values from Day -7 to Day -1 prior to first dose of study treatment (Day 1); post-dose visit i.e. Week 16 used average of 7 daily values from Days 106 to 112 prior to Week 16 (Day 113). Change from Baseline (CFB) was calculated by subtracting Baseline value from the post-dose (PD) visit (Week 16) value.
Time frame: Baseline (Day -7 to Day -1) and Week 16
Number of Participants Who Achieved Reduction of >=4 Points in PP-NRS Score From Baseline at Week 16
PP-NRS is a patient reported measure of pruritus (itch) intensity assessing worst itch (in the past 24 hours). The values were evaluated using an 11-point scale (from 0 to 10), with 0 being no itch and 10 being the worst imaginable itch. Baseline was averaged from daily values from Day -7 to Day -1 prior to first dose of study treatment (Day 1); post-dose visit i.e. Week 16 used average of 7 daily values from Days 106 to 112 prior to Week 16 (Day 113).
Time frame: Baseline (Day -7 to Day -1) and Week 16
Number of Participants Who Achieved Reduction of >=50%, >=90% or 100% in EASI Score From Baseline at Week 16
EASI scoring system is standardized clinical tool for assessment of extent (area) \& severity of atopic dermatitis(AtD). Severity of clinical signs of AtD (erythema, induration/papulation, excoriation \& lichenification) scored separately for each of 4 body regions (head \& neck, upper limbs, trunk \& lower limbs) on 4-point scale: 0=absent;1=mild;2=moderate;3=severe. EASI area score was based upon % body surface area with AtD in body region:0=0%, 1=1-9%;2=10-29%;3=30-49%;4=50-69%;5=70-89%;6=90-100%. Final EASI score was obtained by multiplying EASI area scores (0-6) with severity scores (0-3) of all 4 body regions; it ranges from 0 to 72, with higher scores= more severe or extensive condition. Baseline was the last value/assessment before first dose of study treatment (Day 1) based on date \& time of assessment \& treatment.
Time frame: Baseline (Day 1) and Week 16
Number of Participants Who Achieved Reduction of >=50% or >=75% in Scoring Atopic Dermatitis (SCORAD) Score From Baseline at Week 16
SCORAD was used to standardize the extent and severity of AtD. It consisted of 3 components i.e., A=extent or affected BSA assessed as a % of each defined body area and reported as sum of all areas, with a maximum score of 100%.B=severity of 6 specific symptoms of AtD (redness, swelling, oozing/crusting, excoriation, skin thickening/lichenification, dryness) assessed using following scale: none=0,mild=1,moderate=2, or severe=3 (for a maximum of 18 total points) \& C=pruritus (itch) \& sleep loss scored by participants on VAS, where "0"=no itch(or no sleeplessness) \& "10"=worst imaginable itch(or sleeplessness) with a maximum score of 20. SCORAD total score was calculated using these 3 aspects: extent (A: 0-100), severity (B: 0-18), \& subjective symptoms (C: 0-20) using the formula: A/5 + 7\*B/2+ C. SCORAD total score ranged from 0 to 103, where 0=no disease to 103=severe disease. Higher values of SCORAD=worse outcome.
Time frame: Baseline (Day 1) and Week 16
Change From Baseline in the Body Surface Area (BSA) at Week 16
The BSA assessment estimates the extent of disease or skin involvement with respect to AtD and is expressed as a percentage of total body surface area. BSA were determined by the Investigator or designee using the participant's palm = 1% rule i.e. the surface area of the participant's palm (including fingers) is approximately 1% of the total BSA. Investigators applied this rule to quickly estimate the percentage of skin affected by AtD without complex calculations (for example- if the affected area equals 10 palms, this corresponded to approximately 10% BSA involvement). Baseline was the last value/assessment before the first dose of study treatment (Day 1) based on date and time of the assessment and treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 16) value.
Time frame: Baseline (Day 1) and Week 16
Change From Baseline in the SCORAD Score at Week 16
SCORAD was used to standardize the extent and severity of AtD. It consisted of 3 components i.e., A=extent or affected BSA assessed as a % of each defined body area and reported as sum of all areas, with a maximum score of 100%.B=severity of 6 specific symptoms of AtD (redness, swelling, oozing/crusting, excoriation, skin thickening/lichenification, dryness) assessed using following scale: none=0,mild=1,moderate=2, or severe=3 (for a maximum of 18 total points) \& C=pruritus (itch) \& sleep loss scored by participants on VAS, where "0"=no itch(or no sleeplessness) \& "10"=worst imaginable itch(or sleeplessness) with a maximum score of 20. SCORAD total score was calculated using these 3 aspects: extent (A: 0-100), severity (B: 0-18), \& subjective symptoms (C: 0-20) using the formula: A/5 + 7\*B/2+ C. SCORAD total score ranged from 0 to 103, where 0=no disease to 103=severe disease. Higher values of SCORAD=worse outcome.
Time frame: Baseline (Day 1) and Week 16
Change From Baseline in Patient Reported Outcomes (PRO) Measure of Skin Pain Numerical Rating Scale (SP-NRS) Score at Week 16
SP-NRS is a patient reported measure assessing worst level of skin pain (in the past 24 hours). The values were evaluated using an 11-point scale from 0 to 10, with 0 being no pain and 10 being the worst pain imaginable. Baseline was averaged from daily values from Day -7 to Day -1 prior to first dose of study treatment (Day 1); post-dose visit i.e. Week 16 used average of 7 daily values from Days 106 to 112 prior to Week 16 (Day 113). Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 16) value.
Time frame: Baseline (Day -7 to Day -1) and Week 16
Change From Baseline in PRO Measure of Patient Reported Outcomes Measurement Information System (PROMIS) -Sleep Disturbance 8b at Week 16
The PROMIS sleep disturbance 8b is a PRO instrument designed to assess participant's self-reported sleep disturbance for which the recall period is the past 7 days. It measures perceptions of sleep quality, depth, and restoration associated with sleep. It contains 8 questions (hence "8b"), these questions are rated using 5-point verbal rating scale (i.e., 1 = very much to 5 = not at all). These are summed to get a total score which ranges from 8 to 40, with higher scores indicating greater severity of sleep disturbance. Baseline was the last value/assessment before the first dose of study treatment (Day 1) based on date and time of the assessment and treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 16) value.
Time frame: Baseline (Day 1) and Week 16
Change From Baseline in PRO Measure of Functional Assessment of Chronic Illness Therapy (FACIT) - Fatigue Scale Score at Week 16
The FACIT-Fatigue scale is a short, 13-item measure that assesses participant's self-reported fatigue and its associated impact for daily activities over the past week. The items are rated on a 5-point Likert-type scale: (i.e., 0 = very much to 4 = not at all), where a higher score indicates a better outcome (no fatigue). The total score was derived by summing rating of all 13 items, which ranges from 0 to 52, with 0 being the worst possible score and 52 indicating no fatigue. Higher score indicates an improvement in the participant's health status and decrease in the score indicates worse fatigue/quality of life (QoL). Baseline was the last value/assessment before the first dose of study treatment (Day 1) based on date and time of the assessment and treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 16) value.
Time frame: Baseline (Day 1) and Week 16
Change From Baseline in PRO Measure of Brief Fatigue Inventory (BFI) - Item 3 at Week 16
The BFI is a self-administered questionnaire developed to assess fatigue severity. The BFI has 9 items. BFI- Item 3 assesses the worst level of fatigue during the past 24 hours. Participants report their worst level of fatigue daily, for the previous 24 hours, using a numerical rating scale ranging from 0 (no fatigue) to 10 (as bad as you can imagine). The BFI item 3 score ranges from 0 to 10, higher score indicates worst outcome. Baseline was averaged from daily values from Day -7 to Day -1 prior to first dose of study treatment (Day 1); post-dose visit i.e. Week 16 used average of 7 daily values from Days 106 to 112 prior to Week 16 (Day 113). Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 16) value.
Time frame: Baseline (Day -7 to Day -1) and Week 16
Change From Baseline in PRO Measure of Patient Oriented Eczema Measure (POEM) at Week 16
POEM is a 7-item questionnaire that assesses symptoms of dryness, itching, flaking, cracking, sleep loss, bleeding, and weeping over the last week. Each item is scored from 0 to 4, where 0 = 'no days', 1 = '1 to 2 days', 2 = '3 to 4 days', 3 = '5 to 6' days, and 4 = 'every day'). The total score was derived by summing scores of all 7-items. Total score ranges from 0 (absent disease) to 28 (severe disease). Higher score indicates poor QoL. Baseline was the last value/assessment before the first dose of study treatment (Day 1) based on date and time of the assessment and treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose (Week 16) visit value.
Time frame: Baseline (Day 1) and Week 16
Change From Baseline in PRO Measure of Dermatology Life Quality Index (DLQI) Score at Week 16
The DLQI is a 10-item questionnaire that asks participants to evaluate the degree that their skin disease has affected their QoL. Each question was evaluated on a 4-point scale (range 0 to 3) where, 0 = not at all, 1= a little, 2= a lot, 3= very much, higher scores indicated more impact on quality of life. Scores from all 10 questions were added up to give DLQI total score. The total DLQI score ranges from 0 (not at all) to 30 (very much). Higher scores indicated more impaired quality of life. Baseline was the last value/assessment before the first dose of study treatment (Day 1) based on date and time of the assessment and treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 16) value.
Time frame: Baseline (Day 1) and Week 16
Change From Baseline in PRO Measure of Hospital Anxiety and Depression Scale (HADS) - Anxiety Subscale Score at Week 16
HADS was a validated 14-item self-reported questionnaire to assess states of anxiety and depression over the past week. HADS consisted of 2 subscales: HADS-Anxiety (HADS-A) scale and HADS-Depression (HADS-D) scale. HADS-A assessed state of generalized anxiety. It comprised of 7 items. Each item was rated on a 4-point scale, with scores ranging from 0 (no, not at all) to 3 (yes, definitely), where higher scores indicated more anxiety/depression symptoms. HADS-A total score was calculated as the sum of all 7 items with score ranging from 0 (no presence of anxiety) to 21 (severe feeling of anxiety); higher score indicated greater severity of anxiety. Baseline was the last value/assessment before the first dose of study treatment (Day 1) based on date and time of the assessment and treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 16) value. Data of HADS-anxiety subscale score has been presented.
Time frame: Baseline (Day 1) and Week 16
Change From Baseline in PRO Measure of HADS-Depression Subscale Score at Week 16
HADS was a validated 14-item self-reported questionnaire to assess states of anxiety and depression over the past week. HADS consisted of 2 subscales: HADS-Anxiety (HADS-A) scale and HADS-Depression (HADS-D) scale. HADS-D assessed state of depression. It comprised of 7 items. Each item was rated on a 4-point scale, with scores ranging from 0 (no, not at all) to 3 (yes, definitely), where higher scores indicated more anxiety/depression symptoms. HADS-D total score was calculated as the sum of all 7 items with score ranging from 0 (no presence of depression) to 21 (severe feeling of depression); higher score indicated greater severity of depression. Baseline was the last value/assessment before the first dose of study treatment (Day 1) based on date and time of the assessment and treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 16) value. Data of HADS-depression subscale score has been presented.
Time frame: Baseline (Day 1) and Week 16
Change From Baseline in PRO Measure of Work Productivity and Activity Impairment Questionnaire-Atopic Dermatitis (WPAI- AD) at Week 16
The WPAI-AD is a concise,6-item questionnaire that evaluates the impact of atopic dermatitis on both work and daily activities, yielding 4 percentage-based impairment scores, each range from 0 to 100%. Higher values=greater impairment. Calculation of these 4 scores are as follows: 1. Work time missed due to health (Absenteeism) (%)=hours missed due to health divided by (hours missed due to health+hours missed for other reasons+hours actually worked) \*100. 2. Impairment while working due to health (Presenteeism) (%)=Question (Q)5 score (from 0 to 10) divided by 10\*100. 3. Overall work impairment due to health (%)=Absenteeism+(1-Absenteeism fraction)\*Presenteeism. 4. Activity impairment due to health (%)=Q6 score (from 0 to 10) divided by 10\*100.Baseline was the last value/assessment before the first dose of study treatment (Day1) based on date and time of the assessment and treatment. CFB was calculated by subtracting Baseline value from the post-dose visit (Week 16) value.
Time frame: Baseline (Day 1) and Week 16
Number of Participants With Adverse Events (AEs), Serious AE (SAEs), and AEs of Special Interest (AESI)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with use of a study intervention, whether or not considered related to study intervention. Any untoward medical occurrence that, at any dose, results in death, Is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, Is a congenital anomaly/birth defect in the offspring of a study participant, abnormal pregnancy outcomes, Is a suspected transmission of any infectious agent via an authorized medicinal product and medically important were categorized as SAE. AESIs of the study drug includes serious and opportunistic infections, serious hypersensitivity reactions and injection site reactions.
Time frame: Up to Week 28
Change From Baseline in Hematology Parameter: Hemoglobin (Hb)
Blood samples were collected to analyze hematology parameter: hemoglobin. Baseline was the last value/assessment before the first dose of study treatment (Day 1) based on date and time of the assessment and treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 16) value.
Time frame: Baseline (Day 1) and Week 16
Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils and Platelets
Blood samples were collected to analyze Hematology Parameters: Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils and Platelets. Baseline was the last value/assessment before the first dose of study treatment (Day 1) based on date and time of the assessment and treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 16) value.
Time frame: Baseline (Day 1) and Week 16
Change From Baseline in Hematology Parameter: Erythrocytes
Blood samples were collected to analyze hematology parameter: erythrocytes. Baseline was the last value/assessment before the first dose of study treatment (Day 1) based on date and time of the assessment and treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 16) value.
Time frame: Baseline (Day 1) and Week 16
Change From Baseline in Hematology Parameter: Hematocrit
Blood samples were collected to analyze hematology parameter: hematocrit. Baseline was the last value/assessment before the first dose of study treatment (Day 1) based on date and time of the assessment and treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 16) value.
Time frame: Baseline (Day 1) and Week 16
Change From Baseline in Hematology Parameter: Prothrombin International Normalized Ratio
Blood samples were collected to analyze hematology parameter: Prothrombin International Normalized Ratio. Baseline was the last value/assessment before the first dose of study treatment (Day 1) based on date and time of the assessment and treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 16) value.
Time frame: Baseline (Day 1) and Week 16
Change From Baseline in Clinical Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Gamma-Glutamyl Transferase (GGT)
Blood samples were collected to analyze clinical chemical parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Gamma-Glutamyl Transferase (GGT). Baseline was the last value/assessment before the first dose of study treatment (Day 1) based on date and time of the assessment and treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 16) value.
Time frame: Baseline (Day 1) and Week 16
Change From Baseline in Clinical Chemistry Parameter: Total Bilirubin, Direct Bilirubin, and Creatinine
Blood samples were collected to analyze clinical chemical parameters: Total Bilirubin, Direct Bilirubin, and Creatinine. Baseline was the last value/assessment before the first dose of study treatment (Day 1) based on date and time of the assessment and treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 16) value.
Time frame: Baseline (Day 1) and Week 16
Change From Baseline in Chemistry Parameters: Glucose and Urea
Blood samples were collected to analyze chemistry parameters: glucose and urea. Baseline was the last value/assessment before the first dose of study treatment (Day 1) based on date and time of the assessment and treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 16) value.
Time frame: Baseline (Day 1) and Week 16
Change From Baseline in Chemistry Parameter: Albumin
Blood samples were collected to analyze chemistry parameter: albumin. Baseline was the last value/assessment before the first dose of study treatment (Day 1) based on date and time of the assessment and treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 16) value.
Time frame: Baseline (Day 1) and Week 16
Change From Baseline in Chemistry Parameter: Estimated Glomerular Filtration Rate
Blood samples were collected to analyze chemistry parameter: Estimated Glomerular Filtration Rate. Baseline was the last value/assessment before the first dose of study treatment (Day 1) based on date and time of the assessment and treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 16) value.
Time frame: Baseline (Day 1) and Week 16
Number of Participants With Greater Than or Equal to (>=) Grade 3 Hematological/Clinical Chemistry Abnormalities According to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE)
The laboratory measurements included hematology and clinical chemistry. The parameters evaluated were albumin, glomerular filtration rate from creatinine adjusted for body surface area, glucose, potassium, sodium, alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, creatinine, gamma glutamyl transferase, activated partial thromboplastin time, hemoglobin, leukocytes, lymphocytes, neutrophils, platelets, prothrombin international normalized ratio, eosinophils, and fibrinogen. Worst case grade increase from Baseline grade was evaluated for all the laboratory tests that were gradable by NCI CTCAE. Data is presented for only those parameters for which participants had worst case \>= Grade 3 abnormalities.
Time frame: Up to Week 28
A total of 161 participants were enrolled and randomized, however only 159 participants were included in Full Analysis Set (FAS) as 2 participants were never dosed following randomization. FAS included all randomized participants who received at least 1 dose of study treatment. This population was based on the treatment the participant was randomized to. This study was terminated after meeting the pre-defined futility criteria for efficacy.
| Milestone | Placebo | GSK1070806 Dose Level 1 | GSK1070806 Dose Level 2 | GSK1070806 Dose Level 3 | GSK1070806 Dose Level 4 |
|---|---|---|---|---|---|
| Started | 46 | 22 | 25 | 22 | 46 |
| Full analysis set (fas) | 46 | 21 | 25 | 21 | 46 |
| Completed | 26 | 16 | 18 | 14 | 30 |
| Not completed | 20 | 6 | 7 | 8 | 16 |
| Withdrew: Lost to follow-up | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 9 | 0 | 1 | 3 | 4 |
| Withdrew: Study terminated by sponsor | 10 | 4 | 6 | 4 | 11 |
| Withdrew: Randomized, but did not receive treatment | 0 | 1 | 0 | 1 | 0 |
EASI scoring system is standardized clinical tool for assessment of extent (area) \& severity of atopic dermatitis(AtD). Severity of clinical signs of AtD (erythema, induration/papulation, excoriation \& lichenification) scored separately for each of 4 body regions (head \& neck, upper limbs, trunk \& lower limbs) on 4-point scale: 0=absent;1=mild;2=moderate;3=severe. EASI area score was based upon % body surface area with AtD in body region:0=0%, 1=1-9%;2=10-29%;3=30-49%;4=50-69%;5=70-89%;6=90-100%. Final EASI score was obtained by multiplying EASI area scores (0-6) with severity scores (0-3) of all 4 body regions; it ranges from 0 to 72, with higher scores= more severe or extensive condition. Baseline=last value/assessment before first dose of study treatment (ST) (Day1) based on date \& time of assessment (ToA) \& treatment. CFB =post-dose visit (Week 16) value minus Baseline value. Percent CFB was calculated by dividing CFB value by Baseline value and multiplying it by 100.
| Percent Change | Placebo | GSK1070806 Dose Level 1 | GSK1070806 Dose Level 2 | GSK1070806 Dose Level 3 | GSK1070806 Dose Level 4 |
|---|---|---|---|---|---|
| Percent Change From Baseline (CFB) in Eczema Area and Severity Index (EASI) Score at Week 16 | -44.53 ± 40.805 | -42.86 ± 36.186 | -69.95 ± 33.363 | -41.49 ± 43.341 | -58.08 ± 33.129 |
EASI scoring system is standardized clinical tool for assessment of extent (area) \& severity of atopic dermatitis(AtD). Severity of clinical signs of AtD (erythema, induration/papulation, excoriation \& lichenification) scored separately for each of 4 body regions (head \& neck, upper limbs, trunk \& lower limbs) on 4-point scale: 0=absent;1=mild;2=moderate;3=severe. EASI area score was based upon % body surface area with AtD in body region:0=0%, 1=1-9%;2=10-29%;3=30-49%;4=50-69%;5=70-89%;6=90-100%. Final EASI score was obtained by multiplying EASI area scores (0-6) with severity scores (0-3) of all 4 body regions; it ranges from 0 to 72, with higher scores= more severe or extensive condition. Baseline=last value/assessment before first dose of ST (Day1) based on date \& ToA \& treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Percent CFB was calculated by dividing CFB value by Baseline value and multiplying it by 100.
| Percent Change | Placebo | GSK1070806 Dose Level 1 | GSK1070806 Dose Level 2 | GSK1070806 Dose Level 3 | GSK1070806 Dose Level 4 |
|---|---|---|---|---|---|
| Week 1 | -9.58 ± 27.102 | -26.85 ± 25.180 | -27.05 ± 27.533 | -27.44 ± 29.177 | -14.64 ± 31.257 |
| Week 2 | -26.81 ± 32.253 | -22.63 ± 27.981 | -38.13 ± 25.719 | -21.03 ± 26.151 | -27.31 ± 30.798 |
| Week 4 | -26.75 ± 32.894 | -26.10 ± 27.041 | -48.22 ± 26.242 | -21.80 ± 39.642 | -42.85 ± 33.409 |
| Week 6 | -30.94 ± 40.673 | -26.32 ± 46.858 | -59.53 ± 26.937 | -24.34 ± 46.323 | -53.15 ± 26.140 |
| Week 8 | -35.38 ± 37.223 | -21.48 ± 65.594 | -58.61 ± 29.369 | -29.42 ± 44.434 | -58.66 ± 26.807 |
| Week 10 | -37.23 ± 34.334 | -39.35 ± 32.049 | -62.04 ± 29.196 | -30.54 ± 51.927 | -58.73 ± 31.518 |
| Week 12 | -44.80 ± 32.803 | -40.72 ± 32.538 | -64.63 ± 33.270 | -38.07 ± 49.963 | -59.34 ± 30.652 |
| Week 14 | -47.10 ± 34.574 | -44.43 ± 32.007 | -66.16 ± 31.768 | -40.57 ± 57.553 | -63.84 ± 27.548 |
| Week 16 | -44.53 ± 40.805 | -42.86 ± 36.186 | -69.95 ± 33.363 | -41.49 ± 43.341 | -58.08 ± 33.129 |
EASI scoring system is standardized clinical tool for assessment of extent (area) \& severity of atopic dermatitis(AtD). Severity of clinical signs of AtD (erythema, induration/papulation, excoriation \& lichenification) scored separately for each of 4 body regions (head \& neck, upper limbs, trunk \& lower limbs) on 4-point scale: 0=absent;1=mild;2=moderate;3=severe. EASI area score was based upon % body surface area with AtD in body region:0=0%, 1=1-9%;2=10-29%;3=30-49%;4=50-69%;5=70-89%;6=90-100%. Final EASI score was obtained by multiplying EASI area scores (0-6) with severity scores (0-3) of all 4 body regions; it ranges from 0 to 72, with higher scores= more severe or extensive condition. Baseline was the last value/assessment before first dose of study treatment (Day1) based on date \& time of assessment \& treatment.
| Participants | Placebo | GSK1070806 Dose Level 1 | GSK1070806 Dose Level 2 | GSK1070806 Dose Level 3 | GSK1070806 Dose Level 4 |
|---|---|---|---|---|---|
| Number of Participants Who Achieved Reduction of Greater Than or Equal to (>=) 75 Percent (%) in EASI Score From Baseline at Week 16 | 5 | 4 | 10 | 3 | 10 |
The Investigator Global Assessment (IGA) is a clinical tool for assessing the current state/severity of a participant's atopic dermatitis. It is a static 5-point morphological assessment of overall disease severity determined by the investigator, sub-investigator, or trained healthcare professional with required qualifications on a scale of 0 to 4 where, 0=clear, 1=almost clear, 2=mild, 3=moderate, and 4=severe. Higher score indicates high severity of disease. IGA 0/1 responders are participants whose IGA score is 'Clear' (0) or 'Almost Clear' (1) and had a reduction of \>=2 points from Baseline at Week 16. Baseline was the last value/assessment before the first dose of study treatment (Day 1) based on date and time of the assessment and treatment.
| Participants | Placebo | GSK1070806 Dose Level 1 | GSK1070806 Dose Level 2 | GSK1070806 Dose Level 3 | GSK1070806 Dose Level 4 |
|---|---|---|---|---|---|
| Number of Participants Who Achieved Investigator's Global Assessment (IGA) Score of 0 or 1 and Had a Reduction of >=2 Points From Baseline at Week 16 | 3 | 4 | 5 | 0 | 6 |
PP-NRS is a patient reported measure of pruritus (itch) intensity assessing worst itch (in the past 24 hours). The values were evaluated using an 11-point scale (from 0 to 10), with 0 being no itch and 10 being the worst imaginable itch. Baseline was averaged from daily values from Day -7 to Day -1 prior to first dose of study treatment (Day 1); post-dose visit i.e. Week 16 used average of 7 daily values from Days 106 to 112 prior to Week 16 (Day 113). Change from Baseline (CFB) was calculated by subtracting Baseline value from the post-dose (PD) visit (Week 16) value.
| Scores on a Scale | Placebo | GSK1070806 Dose Level 1 | GSK1070806 Dose Level 2 | GSK1070806 Dose Level 3 | GSK1070806 Dose Level 4 |
|---|---|---|---|---|---|
| Change From Baseline in Peak Pruritus Numerical Rating Scale (PP-NRS) Score at Week 16 | -2.15 ± 2.745 | -1.77 ± 2.240 | -3.09 ± 2.129 | -2.55 ± 2.586 | -2.09 ± 2.376 |
PP-NRS is a patient reported measure of pruritus (itch) intensity assessing worst itch (in the past 24 hours). The values were evaluated using an 11-point scale (from 0 to 10), with 0 being no itch and 10 being the worst imaginable itch. Baseline was averaged from daily values from Day -7 to Day -1 prior to first dose of study treatment (Day 1); post-dose visit i.e. Week 16 used average of 7 daily values from Days 106 to 112 prior to Week 16 (Day 113).
| Participants | Placebo | GSK1070806 Dose Level 1 | GSK1070806 Dose Level 2 | GSK1070806 Dose Level 3 | GSK1070806 Dose Level 4 |
|---|---|---|---|---|---|
| Number of Participants Who Achieved Reduction of >=4 Points in PP-NRS Score From Baseline at Week 16 | 5 | 4 | 6 | 3 | 5 |
EASI scoring system is standardized clinical tool for assessment of extent (area) \& severity of atopic dermatitis(AtD). Severity of clinical signs of AtD (erythema, induration/papulation, excoriation \& lichenification) scored separately for each of 4 body regions (head \& neck, upper limbs, trunk \& lower limbs) on 4-point scale: 0=absent;1=mild;2=moderate;3=severe. EASI area score was based upon % body surface area with AtD in body region:0=0%, 1=1-9%;2=10-29%;3=30-49%;4=50-69%;5=70-89%;6=90-100%. Final EASI score was obtained by multiplying EASI area scores (0-6) with severity scores (0-3) of all 4 body regions; it ranges from 0 to 72, with higher scores= more severe or extensive condition. Baseline was the last value/assessment before first dose of study treatment (Day 1) based on date \& time of assessment \& treatment.
| Participants | Placebo | GSK1070806 Dose Level 1 | GSK1070806 Dose Level 2 | GSK1070806 Dose Level 3 | GSK1070806 Dose Level 4 |
|---|---|---|---|---|---|
| Reduction of >=50% in EASI | 11 | 7 | 14 | 8 | 19 |
| Reduction of >=90% in EASI | 2 | 1 | 8 | 0 | 6 |
| Reduction of 100% in EASI | 0 | 1 | 1 | 0 | 1 |
SCORAD was used to standardize the extent and severity of AtD. It consisted of 3 components i.e., A=extent or affected BSA assessed as a % of each defined body area and reported as sum of all areas, with a maximum score of 100%.B=severity of 6 specific symptoms of AtD (redness, swelling, oozing/crusting, excoriation, skin thickening/lichenification, dryness) assessed using following scale: none=0,mild=1,moderate=2, or severe=3 (for a maximum of 18 total points) \& C=pruritus (itch) \& sleep loss scored by participants on VAS, where "0"=no itch(or no sleeplessness) \& "10"=worst imaginable itch(or sleeplessness) with a maximum score of 20. SCORAD total score was calculated using these 3 aspects: extent (A: 0-100), severity (B: 0-18), \& subjective symptoms (C: 0-20) using the formula: A/5 + 7\*B/2+ C. SCORAD total score ranged from 0 to 103, where 0=no disease to 103=severe disease. Higher values of SCORAD=worse outcome.
| Participants | Placebo | GSK1070806 Dose Level 1 | GSK1070806 Dose Level 2 | GSK1070806 Dose Level 3 | GSK1070806 Dose Level 4 |
|---|---|---|---|---|---|
| Reduction of >=50% in SCORAD | 4 | 1 | 8 | 2 | 6 |
| Reduction of >=75% in SCORAD | 0 | 1 | 2 | 0 | 1 |
The BSA assessment estimates the extent of disease or skin involvement with respect to AtD and is expressed as a percentage of total body surface area. BSA were determined by the Investigator or designee using the participant's palm = 1% rule i.e. the surface area of the participant's palm (including fingers) is approximately 1% of the total BSA. Investigators applied this rule to quickly estimate the percentage of skin affected by AtD without complex calculations (for example- if the affected area equals 10 palms, this corresponded to approximately 10% BSA involvement). Baseline was the last value/assessment before the first dose of study treatment (Day 1) based on date and time of the assessment and treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 16) value.
| Percentage of Body Surface Area | Placebo | GSK1070806 Dose Level 1 | GSK1070806 Dose Level 2 | GSK1070806 Dose Level 3 | GSK1070806 Dose Level 4 |
|---|---|---|---|---|---|
| Change From Baseline in the Body Surface Area (BSA) at Week 16 | -15.26 ± 20.869 | -11.21 ± 13.244 | -23.57 ± 19.012 | -4.39 ± 24.591 | -16.16 ± 11.932 |
SCORAD was used to standardize the extent and severity of AtD. It consisted of 3 components i.e., A=extent or affected BSA assessed as a % of each defined body area and reported as sum of all areas, with a maximum score of 100%.B=severity of 6 specific symptoms of AtD (redness, swelling, oozing/crusting, excoriation, skin thickening/lichenification, dryness) assessed using following scale: none=0,mild=1,moderate=2, or severe=3 (for a maximum of 18 total points) \& C=pruritus (itch) \& sleep loss scored by participants on VAS, where "0"=no itch(or no sleeplessness) \& "10"=worst imaginable itch(or sleeplessness) with a maximum score of 20. SCORAD total score was calculated using these 3 aspects: extent (A: 0-100), severity (B: 0-18), \& subjective symptoms (C: 0-20) using the formula: A/5 + 7\*B/2+ C. SCORAD total score ranged from 0 to 103, where 0=no disease to 103=severe disease. Higher values of SCORAD=worse outcome.
| Scores on a Scale | Placebo | GSK1070806 Dose Level 1 | GSK1070806 Dose Level 2 | GSK1070806 Dose Level 3 | GSK1070806 Dose Level 4 |
|---|---|---|---|---|---|
| Change From Baseline in the SCORAD Score at Week 16 | -19.73 ± 19.060 | -14.69 ± 17.500 | -39.04 ± 14.701 | -20.18 ± 10.072 | -22.09 ± 17.458 |
SP-NRS is a patient reported measure assessing worst level of skin pain (in the past 24 hours). The values were evaluated using an 11-point scale from 0 to 10, with 0 being no pain and 10 being the worst pain imaginable. Baseline was averaged from daily values from Day -7 to Day -1 prior to first dose of study treatment (Day 1); post-dose visit i.e. Week 16 used average of 7 daily values from Days 106 to 112 prior to Week 16 (Day 113). Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 16) value.
| Scores on a Scale | Placebo | GSK1070806 Dose Level 1 | GSK1070806 Dose Level 2 | GSK1070806 Dose Level 3 | GSK1070806 Dose Level 4 |
|---|---|---|---|---|---|
| Change From Baseline in Patient Reported Outcomes (PRO) Measure of Skin Pain Numerical Rating Scale (SP-NRS) Score at Week 16 | -2.0 ± 3.03 | -1.6 ± 2.26 | -3.0 ± 2.08 | -2.5 ± 2.78 | -2.0 ± 2.43 |
The PROMIS sleep disturbance 8b is a PRO instrument designed to assess participant's self-reported sleep disturbance for which the recall period is the past 7 days. It measures perceptions of sleep quality, depth, and restoration associated with sleep. It contains 8 questions (hence "8b"), these questions are rated using 5-point verbal rating scale (i.e., 1 = very much to 5 = not at all). These are summed to get a total score which ranges from 8 to 40, with higher scores indicating greater severity of sleep disturbance. Baseline was the last value/assessment before the first dose of study treatment (Day 1) based on date and time of the assessment and treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 16) value.
| Scores on a Scale | Placebo | GSK1070806 Dose Level 1 | GSK1070806 Dose Level 2 | GSK1070806 Dose Level 3 | GSK1070806 Dose Level 4 |
|---|---|---|---|---|---|
| Change From Baseline in PRO Measure of Patient Reported Outcomes Measurement Information System (PROMIS) -Sleep Disturbance 8b at Week 16 | -5.29 ± 9.281 | -4.83 ± 8.330 | -9.70 ± 7.864 | -5.89 ± 7.846 | -5.27 ± 7.402 |
The FACIT-Fatigue scale is a short, 13-item measure that assesses participant's self-reported fatigue and its associated impact for daily activities over the past week. The items are rated on a 5-point Likert-type scale: (i.e., 0 = very much to 4 = not at all), where a higher score indicates a better outcome (no fatigue). The total score was derived by summing rating of all 13 items, which ranges from 0 to 52, with 0 being the worst possible score and 52 indicating no fatigue. Higher score indicates an improvement in the participant's health status and decrease in the score indicates worse fatigue/quality of life (QoL). Baseline was the last value/assessment before the first dose of study treatment (Day 1) based on date and time of the assessment and treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 16) value.
| Scores on a Scale | Placebo | GSK1070806 Dose Level 1 | GSK1070806 Dose Level 2 | GSK1070806 Dose Level 3 | GSK1070806 Dose Level 4 |
|---|---|---|---|---|---|
| Change From Baseline in PRO Measure of Functional Assessment of Chronic Illness Therapy (FACIT) - Fatigue Scale Score at Week 16 | 5.30 ± 10.363 | 6.26 ± 11.808 | 10.57 ± 10.865 | 2.33 ± 7.219 | 7.14 ± 11.738 |
The BFI is a self-administered questionnaire developed to assess fatigue severity. The BFI has 9 items. BFI- Item 3 assesses the worst level of fatigue during the past 24 hours. Participants report their worst level of fatigue daily, for the previous 24 hours, using a numerical rating scale ranging from 0 (no fatigue) to 10 (as bad as you can imagine). The BFI item 3 score ranges from 0 to 10, higher score indicates worst outcome. Baseline was averaged from daily values from Day -7 to Day -1 prior to first dose of study treatment (Day 1); post-dose visit i.e. Week 16 used average of 7 daily values from Days 106 to 112 prior to Week 16 (Day 113). Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 16) value.
| Scores on a Scale | Placebo | GSK1070806 Dose Level 1 | GSK1070806 Dose Level 2 | GSK1070806 Dose Level 3 | GSK1070806 Dose Level 4 |
|---|---|---|---|---|---|
| Change From Baseline in PRO Measure of Brief Fatigue Inventory (BFI) - Item 3 at Week 16 | -1.59 ± 2.999 | -1.20 ± 1.974 | -2.59 ± 2.441 | -2.12 ± 2.469 | -1.84 ± 2.241 |
POEM is a 7-item questionnaire that assesses symptoms of dryness, itching, flaking, cracking, sleep loss, bleeding, and weeping over the last week. Each item is scored from 0 to 4, where 0 = 'no days', 1 = '1 to 2 days', 2 = '3 to 4 days', 3 = '5 to 6' days, and 4 = 'every day'). The total score was derived by summing scores of all 7-items. Total score ranges from 0 (absent disease) to 28 (severe disease). Higher score indicates poor QoL. Baseline was the last value/assessment before the first dose of study treatment (Day 1) based on date and time of the assessment and treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose (Week 16) visit value.
| Scores on a Scale | Placebo | GSK1070806 Dose Level 1 | GSK1070806 Dose Level 2 | GSK1070806 Dose Level 3 | GSK1070806 Dose Level 4 |
|---|---|---|---|---|---|
| Change From Baseline in PRO Measure of Patient Oriented Eczema Measure (POEM) at Week 16 | -4.36 ± 7.427 | -4.59 ± 5.917 | -8.58 ± 7.058 | -4.63 ± 4.745 | -7.68 ± 8.759 |
The DLQI is a 10-item questionnaire that asks participants to evaluate the degree that their skin disease has affected their QoL. Each question was evaluated on a 4-point scale (range 0 to 3) where, 0 = not at all, 1= a little, 2= a lot, 3= very much, higher scores indicated more impact on quality of life. Scores from all 10 questions were added up to give DLQI total score. The total DLQI score ranges from 0 (not at all) to 30 (very much). Higher scores indicated more impaired quality of life. Baseline was the last value/assessment before the first dose of study treatment (Day 1) based on date and time of the assessment and treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 16) value.
| Scores on a Scale | Placebo | GSK1070806 Dose Level 1 | GSK1070806 Dose Level 2 | GSK1070806 Dose Level 3 | GSK1070806 Dose Level 4 |
|---|---|---|---|---|---|
| Change From Baseline in PRO Measure of Dermatology Life Quality Index (DLQI) Score at Week 16 | -5.00 ± 8.477 | -4.63 ± 8.321 | -8.48 ± 8.424 | -3.94 ± 6.458 | -7.56 ± 7.201 |
HADS was a validated 14-item self-reported questionnaire to assess states of anxiety and depression over the past week. HADS consisted of 2 subscales: HADS-Anxiety (HADS-A) scale and HADS-Depression (HADS-D) scale. HADS-A assessed state of generalized anxiety. It comprised of 7 items. Each item was rated on a 4-point scale, with scores ranging from 0 (no, not at all) to 3 (yes, definitely), where higher scores indicated more anxiety/depression symptoms. HADS-A total score was calculated as the sum of all 7 items with score ranging from 0 (no presence of anxiety) to 21 (severe feeling of anxiety); higher score indicated greater severity of anxiety. Baseline was the last value/assessment before the first dose of study treatment (Day 1) based on date and time of the assessment and treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 16) value. Data of HADS-anxiety subscale score has been presented.
| Scores on a Scale | Placebo | GSK1070806 Dose Level 1 | GSK1070806 Dose Level 2 | GSK1070806 Dose Level 3 | GSK1070806 Dose Level 4 |
|---|---|---|---|---|---|
| Change From Baseline in PRO Measure of Hospital Anxiety and Depression Scale (HADS) - Anxiety Subscale Score at Week 16 | -0.67 ± 3.585 | -1.05 ± 2.297 | -2.21 ± 3.735 | -0.50 ± 4.356 | -1.94 ± 4.183 |
HADS was a validated 14-item self-reported questionnaire to assess states of anxiety and depression over the past week. HADS consisted of 2 subscales: HADS-Anxiety (HADS-A) scale and HADS-Depression (HADS-D) scale. HADS-D assessed state of depression. It comprised of 7 items. Each item was rated on a 4-point scale, with scores ranging from 0 (no, not at all) to 3 (yes, definitely), where higher scores indicated more anxiety/depression symptoms. HADS-D total score was calculated as the sum of all 7 items with score ranging from 0 (no presence of depression) to 21 (severe feeling of depression); higher score indicated greater severity of depression. Baseline was the last value/assessment before the first dose of study treatment (Day 1) based on date and time of the assessment and treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 16) value. Data of HADS-depression subscale score has been presented.
| Scores on a Scale | Placebo | GSK1070806 Dose Level 1 | GSK1070806 Dose Level 2 | GSK1070806 Dose Level 3 | GSK1070806 Dose Level 4 |
|---|---|---|---|---|---|
| Change From Baseline in PRO Measure of HADS-Depression Subscale Score at Week 16 | -1.53 ± 3.803 | -0.84 ± 2.734 | -1.11 ± 3.635 | 0.50 ± 3.650 | -1.88 ± 3.982 |
The WPAI-AD is a concise,6-item questionnaire that evaluates the impact of atopic dermatitis on both work and daily activities, yielding 4 percentage-based impairment scores, each range from 0 to 100%. Higher values=greater impairment. Calculation of these 4 scores are as follows: 1. Work time missed due to health (Absenteeism) (%)=hours missed due to health divided by (hours missed due to health+hours missed for other reasons+hours actually worked) \*100. 2. Impairment while working due to health (Presenteeism) (%)=Question (Q)5 score (from 0 to 10) divided by 10\*100. 3. Overall work impairment due to health (%)=Absenteeism+(1-Absenteeism fraction)\*Presenteeism. 4. Activity impairment due to health (%)=Q6 score (from 0 to 10) divided by 10\*100.Baseline was the last value/assessment before the first dose of study treatment (Day1) based on date and time of the assessment and treatment. CFB was calculated by subtracting Baseline value from the post-dose visit (Week 16) value.
| Scores on a Scale | Placebo | GSK1070806 Dose Level 1 | GSK1070806 Dose Level 2 | GSK1070806 Dose Level 3 | GSK1070806 Dose Level 4 |
|---|---|---|---|---|---|
| Work time missed due to health | -4.43 ± 9.294 | 15.76 ± 32.405 | -4.54 ± 28.375 | -1.31 ± 8.937 | -0.84 ± 21.263 |
| Impairment while working due to health | -20.00 ± 46.726 | -23.33 ± 34.641 | -15.45 ± 23.394 | -14.17 ± 19.752 | -9.41 ± 32.301 |
| Overall work impairment due to health | -21.23 ± 44.566 | -21.48 ± 36.722 | -13.59 ± 24.074 | -13.33 ± 20.117 | -8.14 ± 35.238 |
| Activity impairment due to health | -24.67 ± 38.572 | -15.56 ± 27.912 | -26.32 ± 22.903 | -13.33 ± 27.865 | -21.21 ± 28.147 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with use of a study intervention, whether or not considered related to study intervention. Any untoward medical occurrence that, at any dose, results in death, Is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, Is a congenital anomaly/birth defect in the offspring of a study participant, abnormal pregnancy outcomes, Is a suspected transmission of any infectious agent via an authorized medicinal product and medically important were categorized as SAE. AESIs of the study drug includes serious and opportunistic infections, serious hypersensitivity reactions and injection site reactions.
| Participants | Placebo | GSK1070806 Dose Level 1 | GSK1070806 Dose Level 2 | GSK1070806 Dose Level 3 | GSK1070806 Dose Level 4 |
|---|---|---|---|---|---|
| AEs | 21 | 12 | 15 | 13 | 23 |
| SAEs | 0 | 0 | 0 | 1 | 1 |
| AESIs | 0 | 0 | 0 | 1 | 1 |
Blood samples were collected to analyze hematology parameter: hemoglobin. Baseline was the last value/assessment before the first dose of study treatment (Day 1) based on date and time of the assessment and treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 16) value.
| Grams per Liter | Placebo | GSK1070806 Dose Level 1 | GSK1070806 Dose Level 2 | GSK1070806 Dose Level 3 | GSK1070806 Dose Level 4 |
|---|---|---|---|---|---|
| Change From Baseline in Hematology Parameter: Hemoglobin (Hb) | -2.3 ± 7.07 | 0.5 ± 15.12 | -0.3 ± 11.45 | -3.7 ± 3.95 | -1.1 ± 8.60 |
Blood samples were collected to analyze Hematology Parameters: Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils and Platelets. Baseline was the last value/assessment before the first dose of study treatment (Day 1) based on date and time of the assessment and treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 16) value.
| 10^9 cells per liter | Placebo | GSK1070806 Dose Level 1 | GSK1070806 Dose Level 2 | GSK1070806 Dose Level 3 | GSK1070806 Dose Level 4 |
|---|---|---|---|---|---|
| Basophils | -0.008 ± 0.0380 | 0.004 ± 0.0299 | -0.004 ± 0.0372 | 0.004 ± 0.0342 | -0.007 ± 0.0342 |
| Eosinophils | 0.020 ± 0.5437 | -0.187 ± 0.3651 | 0.053 ± 0.2918 | -0.139 ± 0.4575 | -0.044 ± 0.3114 |
| Leukocytes | -0.92 ± 4.050 | 0.35 ± 1.512 | -0.05 ± 1.452 | 0.49 ± 2.388 | -0.21 ± 1.978 |
| Lymphocytes | -0.084 ± 0.5202 | 0.066 ± 0.5162 | 0.071 ± 0.5737 | 0.256 ± 0.4943 | 0.123 ± 0.3357 |
| Monocytes | -0.062 ± 0.2711 | -0.012 ± 0.1389 | 0.007 ± 0.1614 | -0.120 ± 0.1966 | -0.056 ± 0.1478 |
| Neutrophils | -0.782 ± 3.8072 | 0.481 ± 1.5835 | -0.183 ± 1.1484 | 0.489 ± 2.1748 | -0.234 ± 1.9582 |
| Platelets | 3.3 ± 39.86 | -13.2 ± 32.91 | 1.5 ± 29.49 | -7.3 ± 43.32 | -3.0 ± 30.33 |
Blood samples were collected to analyze hematology parameter: erythrocytes. Baseline was the last value/assessment before the first dose of study treatment (Day 1) based on date and time of the assessment and treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 16) value.
| 10^12 cells per liter | Placebo | GSK1070806 Dose Level 1 | GSK1070806 Dose Level 2 | GSK1070806 Dose Level 3 | GSK1070806 Dose Level 4 |
|---|---|---|---|---|---|
| Change From Baseline in Hematology Parameter: Erythrocytes | -0.04 ± 0.215 | 0.11 ± 0.482 | 0.03 ± 0.330 | -0.09 ± 0.145 | -0.04 ± 0.243 |
Blood samples were collected to analyze hematology parameter: hematocrit. Baseline was the last value/assessment before the first dose of study treatment (Day 1) based on date and time of the assessment and treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 16) value.
| Proportion of red blood cells in blood | Placebo | GSK1070806 Dose Level 1 | GSK1070806 Dose Level 2 | GSK1070806 Dose Level 3 | GSK1070806 Dose Level 4 |
|---|---|---|---|---|---|
| Change From Baseline in Hematology Parameter: Hematocrit | -0.0031 ± 0.0273 | 0.0047 ± 0.0427 | 0.0014 ± 0.0301 | -0.0100 ± 0.0155 | 0.0022 ± 0.0230 |
Blood samples were collected to analyze hematology parameter: Prothrombin International Normalized Ratio. Baseline was the last value/assessment before the first dose of study treatment (Day 1) based on date and time of the assessment and treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 16) value.
| Ratio | Placebo | GSK1070806 Dose Level 1 | GSK1070806 Dose Level 2 | GSK1070806 Dose Level 3 | GSK1070806 Dose Level 4 |
|---|---|---|---|---|---|
| Change From Baseline in Hematology Parameter: Prothrombin International Normalized Ratio | -0.021 ± 0.1172 | -0.042 ± 0.1522 | -0.036 ± 0.1487 | 0.052 ± 0.2580 | -0.038 ± 0.1525 |
Blood samples were collected to analyze clinical chemical parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Gamma-Glutamyl Transferase (GGT). Baseline was the last value/assessment before the first dose of study treatment (Day 1) based on date and time of the assessment and treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 16) value.
| International Units per Liter | Placebo | GSK1070806 Dose Level 1 | GSK1070806 Dose Level 2 | GSK1070806 Dose Level 3 | GSK1070806 Dose Level 4 |
|---|---|---|---|---|---|
| ALT | -2.6 ± 12.94 | -3.7 ± 16.80 | -2.2 ± 14.25 | -2.0 ± 10.65 | -1.8 ± 7.82 |
| ALP | -2.4 ± 19.19 | -6.4 ± 18.87 | -1.8 ± 11.51 | -2.3 ± 11.33 | -6.1 ± 9.45 |
| AST | -2.2 ± 10.47 | -4.9 ± 10.93 | -2.5 ± 5.78 | -3.6 ± 7.51 | -1.1 ± 5.99 |
| GGT | -3.3 ± 19.99 | 0.3 ± 16.57 | -1.1 ± 3.50 | 1.6 ± 12.72 | 0.5 ± 6.36 |
Blood samples were collected to analyze clinical chemical parameters: Total Bilirubin, Direct Bilirubin, and Creatinine. Baseline was the last value/assessment before the first dose of study treatment (Day 1) based on date and time of the assessment and treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 16) value.
| Micromoles per (/) Liter | Placebo | GSK1070806 Dose Level 1 | GSK1070806 Dose Level 2 | GSK1070806 Dose Level 3 | GSK1070806 Dose Level 4 |
|---|---|---|---|---|---|
| Total Bilirubin | 0.2 ± 4.40 | 0.2 ± 4.54 | 0.2 ± 5.10 | -0.5 ± 2.52 | -1.8 ± 4.29 |
| Direct Bilirubin | 0.2 ± 0.88 | 0.1 ± 1.09 | 0.0 ± 1.43 | -0.2 ± 0.69 | -0.2 ± 0.76 |
| Creatinine | 0.2 ± 5.33 | -0.3 ± 9.22 | 1.4 ± 12.48 | 0.7 ± 5.89 | -2.8 ± 8.13 |
Blood samples were collected to analyze chemistry parameters: glucose and urea. Baseline was the last value/assessment before the first dose of study treatment (Day 1) based on date and time of the assessment and treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 16) value.
| Millimoles per liter | Placebo | GSK1070806 Dose Level 1 | GSK1070806 Dose Level 2 | GSK1070806 Dose Level 3 | GSK1070806 Dose Level 4 |
|---|---|---|---|---|---|
| Glucose | -0.03 ± 0.618 | 0.01 ± 0.675 | 0.25 ± 0.714 | 0.02 ± 0.910 | 0.04 ± 0.781 |
| Urea | -0.31 ± 1.046 | -0.19 ± 1.332 | 0.14 ± 1.228 | 0.00 ± 0.960 | 0.21 ± 1.267 |
Blood samples were collected to analyze chemistry parameter: albumin. Baseline was the last value/assessment before the first dose of study treatment (Day 1) based on date and time of the assessment and treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 16) value.
| Grams per liter | Placebo | GSK1070806 Dose Level 1 | GSK1070806 Dose Level 2 | GSK1070806 Dose Level 3 | GSK1070806 Dose Level 4 |
|---|---|---|---|---|---|
| Change From Baseline in Chemistry Parameter: Albumin | 0.3 ± 2.60 | -0.2 ± 3.25 | 0.0 ± 3.29 | -1.4 ± 2.19 | -0.6 ± 2.07 |
Blood samples were collected to analyze chemistry parameter: Estimated Glomerular Filtration Rate. Baseline was the last value/assessment before the first dose of study treatment (Day 1) based on date and time of the assessment and treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 16) value.
| Milliliter/second/1.73 square meter | Placebo | GSK1070806 Dose Level 1 | GSK1070806 Dose Level 2 | GSK1070806 Dose Level 3 | GSK1070806 Dose Level 4 |
|---|---|---|---|---|---|
| Change From Baseline in Chemistry Parameter: Estimated Glomerular Filtration Rate | -0.0085 ± 0.09674 | -0.0055 ± 0.15910 | -0.0401 ± 0.22359 | -0.0131 ± 0.09838 | 0.0454 ± 0.17785 |
The laboratory measurements included hematology and clinical chemistry. The parameters evaluated were albumin, glomerular filtration rate from creatinine adjusted for body surface area, glucose, potassium, sodium, alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, creatinine, gamma glutamyl transferase, activated partial thromboplastin time, hemoglobin, leukocytes, lymphocytes, neutrophils, platelets, prothrombin international normalized ratio, eosinophils, and fibrinogen. Worst case grade increase from Baseline grade was evaluated for all the laboratory tests that were gradable by NCI CTCAE. Data is presented for only those parameters for which participants had worst case \>= Grade 3 abnormalities.
| Participants | Placebo | GSK1070806 Dose Level 1 | GSK1070806 Dose Level 2 | GSK1070806 Dose Level 3 | GSK1070806 Dose Level 4 |
|---|---|---|---|---|---|
| Number of Participants With Greater Than or Equal to (>=) Grade 3 Hematological/Clinical Chemistry Abnormalities According to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) | 1 | 1 | 0 | 1 | 2 |
Collected over Up to Week 28. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/46 (0%) | 0/46 (0%) | 10/46 (21.7%) |
| GSK1070806 Dose Level 1 | 0/21 (0%) | 0/21 (0%) | 5/21 (23.8%) |
| GSK1070806 Dose Level 2 | 0/25 (0%) | 0/25 (0%) | 9/25 (36%) |
| GSK1070806 Dose Level 3 | 0/21 (0%) | 1/21 (4.8%) | 9/21 (42.9%) |
| GSK1070806 Dose Level 4 | 0/46 (0%) | 1/46 (2.2%) | 12/46 (26.1%) |
| Event | Placebo | GSK1070806 Dose Level 1 | GSK1070806 Dose Level 2 | GSK1070806 Dose Level 3 | GSK1070806 Dose Level 4 |
|---|---|---|---|---|---|
| Hodgkin's disease nodular sclerosisNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/46 | 0/21 | 0/25 | 1/21 | 0/46 |
| Generalised tonic-clonic seizureNervous system disorders | 0/46 | 0/21 | 0/25 | 0/21 | 1/46 |
| Event | Placebo | GSK1070806 Dose Level 1 | GSK1070806 Dose Level 2 | GSK1070806 Dose Level 3 | GSK1070806 Dose Level 4 |
|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 1/46 | 1/21 | 2/25 | 5/21 | 7/46 |
| HeadacheNervous system disorders | 3/46 | 0/21 | 0/25 | 4/21 | 1/46 |
| Dermatitis atopicSkin and subcutaneous tissue disorders | 2/46 | 4/21 | 1/25 | 1/21 | 1/46 |
| FolliculitisInfections and infestations | 1/46 | 0/21 | 0/25 | 3/21 | 2/46 |
| EosinophiliaBlood and lymphatic system disorders | 0/46 | 0/21 | 0/25 | 2/21 | 1/46 |
| HordeolumInfections and infestations | 0/46 | 0/21 | 0/25 | 2/21 | 0/46 |
| PruritusSkin and subcutaneous tissue disorders | 1/46 | 1/21 | 1/25 | 2/21 | 2/46 |
| SinusitisInfections and infestations | 0/46 | 1/21 | 2/25 | 1/21 | 0/46 |
| Back painMusculoskeletal and connective tissue disorders | 0/46 | 0/21 | 2/25 | 0/21 | 1/46 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 0/46 | 0/21 | 2/25 | 0/21 | 0/46 |
Baseline characteristics were reported for Full Analysis Set (FAS) which included all randomized participants who received at least 1 dose of study treatment. This population was based on the treatment the participant was randomized to.
| Age, Continuous(YEARS) | Placebo | GSK1070806 Dose Level 1 | GSK1070806 Dose Level 2 | GSK1070806 Dose Level 3 | GSK1070806 Dose Level 4 | Total |
|---|---|---|---|---|---|---|
| Mean | 37.7 ± 14.42 | 34.1 ± 12.72 | 39.2 ± 14.94 | 35.3 ± 8.96 | 40.1 ± 13.60 | 37.8 ± 13.45 |
| Sex: Female, Male(Participants) | Placebo | GSK1070806 Dose Level 1 | GSK1070806 Dose Level 2 | GSK1070806 Dose Level 3 | GSK1070806 Dose Level 4 | Total |
|---|---|---|---|---|---|---|
| Female | 23 | 7 | 8 | 10 | 19 | 67 |
| Male | 23 | 14 | 17 | 11 | 27 | 92 |
| Race/Ethnicity, Customized(Participants) | Placebo | GSK1070806 Dose Level 1 | GSK1070806 Dose Level 2 | GSK1070806 Dose Level 3 | GSK1070806 Dose Level 4 | Total |
|---|---|---|---|---|---|---|
| AMERICAN INDIAN OR ALASKA NATIVE | 2 | 1 | 1 | 1 | 1 | 6 |
| ASIAN | 15 | 8 | 9 | 6 | 16 | 54 |
| BLACK OR AFRICAN AMERICAN | 4 | 0 | 0 | 2 | 6 | 12 |
| WHITE | 20 | 10 | 11 | 10 | 20 | 71 |
| MIXED RACE | 3 | 1 | 0 | 1 | 0 | 5 |
| NOT REPORTED | 2 | 1 | 2 | 1 | 2 | 8 |
| UNKNOWN | 0 | 0 | 2 | 0 | 1 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
Data sharing details ↗ · www.gsk.com
Ran from Nov 2023 to primary completion in Jul 2025, 20 months.
Results were first posted in Jun 2026, 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: GSK1070806